Axsome Therapeutics Inc(NASDAQ:AXSM) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Earnings per share were $-0.36. Analysts had estimated an EPS of $-0.39.
Several Insider Transactions has been reported to the SEC. On Dec 24, 2015, Randall Kaye (Chief Medical Officer) purchased 1,000 shares at $9.03 per share price.
Axsome Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies for the management of pain and other central nervous system (CNS) disorders. The Company’s product AXS-02 is an oral targeted and non-opioid therapeutic for chronic pain. It is developing AXS-02 for the treatment of pain in three conditions: complex regional pain syndrome (CRPS); knee osteoarthritis associated with bone marrow lesions (BMLs); and chronic low back pain (CLBP) associated with type 1 or mixed type 1 and type 2 Modic changes (MCs). Its AXS-05 is a fixed-dose combination of dextromethorphan (DM) and bupropion. It is developing AXS-05 for the treatment of two conditions: treatment resistant depression (TRD) and agitation in patients with Alzheimer’s disease (AD). Its AXS-05 has completed Phase II trials. The Company also have one active program AXS-06 in preclinical development which is developed for the treatment of chronic pain disorders.